NasdaqCM - Nasdaq Real Time Price USD

vTv Therapeutics Inc. (VTVT)

19.09

-0.36

(-1.85%)

As of 12:31:53 PM EDT. Market Open.

vTv Therapeutics Appoints Michael Tung, M.D., MBA, to Chief Financial Officer as Company Reinitiates Phase 3 Trial of Oral T1D Adjunctive Therapy to Insulin

HIGH POINT, N.C., May 19, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company, today announced the appointment of Michael Tung, M.D., MBA as Executive Vice President and Chief Financial Officer, effective immediately. Dr. Tung joins the Company with 20 years of diversified finance, corporate strategy, investor relations, and business development experience in the biopharmaceutical industry. This executive appointment comes at an important time fo

GlobeNewswire 4 days ago

VTVT
-1.85%
VTv Therapeutics: Q1 Earnings Snapshot

HIGH POINT, N.C. (AP) — VTv Therapeutics Inc. VTVT) on Thursday reported a loss of $5.1 million in its first quarter. On a per-share basis, the High Point, North Carolina-based company said it had a loss of 77 cents.

Associated Press Finance 7 days ago

VTVT
-1.85%
vTv Therapeutics Announces 2025 First Quarter Financial Results and Provides Corporate Update

Ongoing screening in CATT1 Phase 3 trial evaluating cadisegliatin in patients with type 1 diabetes (T1D) Topline Phase 3 data for cadisegliatin expected in 2H 2026 HIGH POINT, N.C., May 15, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin, a potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today reported financial results f

GlobeNewswire 7 days ago

VTVT
-1.85%
vTv Therapeutics Announces Reinitiation of Screening in CATT1 Phase 3 Trial Evaluating Potential First-in-Class Liver-Selective Glucokinase Activator Cadisegliatin for Type 1 Diabetes

Topline CATT1 Phase 3 data is expected in 2H 2026 Protocol amendment shortens trial duration from 12 to 6 months, expediting time to topline data HIGH POINT, N.C., May 15, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company with an innovative clinical portfolio of small molecules and lead program in diabetes, today announced that screening has been reinitiated in the Company’s CATT1 Phase 3 trial investigating cadisegliatin as an adjunctive treat

GlobeNewswire 8 days ago

VTVT
-1.85%
The Zacks Analyst Blog Highlights Sarepta Therapeutics, Incyte, Gilead Sciences and VTv Therapeutics

Sarepta Therapeutics, Incyte, Gilead Sciences and VTv Therapeutics are included in this Analyst Blog.

Zacks 2 months ago

SRPT

VTVT
-1.85%

GILD
VTv Therapeutics: Q4 Earnings Snapshot

On a per-share basis, the High Point, North Carolina-based company said it had a loss of 55 cents. The biopharmaceutical company posted revenue of $17,000 in the period. For the year, the company reported a loss of $18.5 million, or $3.20 per share.

Associated Press Finance 2 months ago

VTVT
-1.85%
vTv Therapeutics Announces 2024 Fourth Quarter and Full Year Financial Results and Provides Corporate Update

Clinical hold lifted for late stage cadisegliatin program for diabetes CATT1 Phase 3 trial in patients with type 1 diabetes (T1D) expected to resume Q2 2025 Strengthens commercial leadership with appointment of Martin Lafontaine as Chief Commercial Officer HIGH POINT, N.C., March 20, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin, a potential first-in-class oral adjunctive therapy to insulin be

GlobeNewswire 2 months ago

VTVT
-1.85%
FDA removes hold on vTv’s cadisegliatin clinical programme for diabetes

Last July, the agency placed a hold on the trial due to a chromatographic signal detected in a human ADME study of the therapy.

Clinical Trials Arena 2 months ago

VTVT
-1.85%
vTv Therapeutics Soars 43% as FDA Lifts Clinical Hold on Diabetes Drug Trial

The company plans to resume its CATT1 Phase 3 trial for type 1 diabetes after submitting a protocol amendment.

GuruFocus.com 2 months ago

VTVT
-1.85%
FDA Lifts Clinical Hold-vTv Stock Jumps Nearly 28% on Diabetes Drug Progress

FDA clears vTv's cadisegliatin trial, prompting a 27.87% stock surge as the company fast-tracks pivotal studies

GuruFocus.com 2 months ago

VTVT
-1.85%
vTv Therapeutics Announces FDA has Lifted Clinical Hold on Cadisegliatin Program for Diabetes

Cadisegliatin has the potential to be the first oral adjunct therapy for type 1 diabetes CATT1 Phase 3 trial expected to resume following submission of protocol amendment shortening the overall duration of the trial from 12 to 6 months HIGH POINT, N.C., March 17, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin, a potential first-in-class oral adjunctive therapy to insulin being investigated for

GlobeNewswire 2 months ago

VTVT
-1.85%
We're Keeping An Eye On vTv Therapeutics' (NASDAQ:VTVT) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Simply Wall St. 3 months ago

VTVT
-1.85%
CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF BRAIN METASTASIS FROM BREAST CANCER

Cantex Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on developing transformative therapies for cancer and other life-threatening medical conditions, announced today that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation to Cantex's azeliragon for the treatment of brain metastasis from breast cancer. This new azeliragon designation adds to azeliragon's two other Orphan Drug Designations for the treatment of pancreatic cancer and glioblastoma, re

PR Newswire 5 months ago

VTVT
-1.85%
vTv Therapeutics to Participate in 7th Annual Evercore HealthCONx Conference

HIGH POINT, N.C., Dec. 02, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company with a portfolio of novel small molecules and a lead program in diabetes, today announced that management will participate in a fireside chat and be available for one-on-one meetings at the 7th Annual Evercore HealthCONx Conference to be held in Coral Gables. Florida, December 3 – 5, 2024. 7th Annual Evercore HealthCONx Conference Presentation Date:December 4, 2024

GlobeNewswire 5 months ago

VTVT
-1.85%
vTv Therapeutics (NASDAQ:VTVT) adds US$9.5m to market cap in the past 7 days, though investors from five years ago are still down 71%

vTv Therapeutics Inc. ( NASDAQ:VTVT ) shareholders should be happy to see the share price up 29% in the last week. But...

Simply Wall St. 6 months ago

VTVT
-1.85%
VTv Therapeutics: Q3 Earnings Snapshot

HIGH POINT, N.C. (AP) — VTv Therapeutics Inc. VTVT) on Tuesday reported a loss of $4.8 million in its third quarter. On a per-share basis, the High Point, North Carolina-based company said it had a loss of 88 cents.

Associated Press Finance 6 months ago

VTVT
-1.85%
vTv Therapeutics Announces 2024 Third Quarter Financial Results and Provides Corporate Update

HIGH POINT, N.C., Nov. 12, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company with a portfolio of novel small molecules and a lead program in diabetes, today reported financial results for the third quarter ended September 30, 2024, and provided an update on recent corporate developments. "Our cadisegliatin program continues to show promise as a new oral adjunct therapy being investigated for improvement in glycemic control and reduction of

GlobeNewswire 6 months ago

VTVT
-1.85%
vTv Therapeutics Faces License Agreement Termination

vTv Therapeutics ( (VTVT) ) has issued an update. OnKure Therapeutics plans to terminate its License Agreement with vTv Therapeutics LLC, ending the development of the ppar-δ agonist program. This move, effective January 2025, might impact investors interested in the pharmaceutical collaborations and the future of vTv’s intellectual property ventures. Learn more about VTVT stock on TipRanks’ Stock Analysis page.

TipRanks 6 months ago

VTVT
-1.85%
VTv Therapeutics: Q2 Earnings Snapshot

HIGH POINT, N.C. (AP) — VTv Therapeutics Inc. VTVT) on Thursday reported a loss of $5.2 million in its second quarter. On a per-share basis, the High Point, North Carolina-based company said it had a loss of 81 cents.

Associated Press Finance 9 months ago

VTVT
-1.85%
vTv Therapeutics Announces 2024 Second Quarter Financial Results and Provides Corporate Update

Screened first patient in cadisegliatin pivotal trial for type 1 diabetes (T1D); working to resolve clinical hold Expanded Newsoara Biopharma license agreement for PDE4 inhibitor HPP737 to a global license effective upon payment of the $20 million upfront fee HIGH POINT, N.C., Aug. 08, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company with an innovative clinical portfolio of small molecules and lead program in diabetes, today reported financial

GlobeNewswire 9 months ago

VTVT
-1.85%

Performance Overview

Return	VTVT	S&P 500 (^GSPC)
YTD	+38.24%	-0.96%
1-Year	-33.94%	+10.58%
3-Year	-3.97%	+46.60%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

vTv Therapeutics Inc. (VTVT)

vTv Therapeutics Appoints Michael Tung, M.D., MBA, to Chief Financial Officer as Company Reinitiates Phase 3 Trial of Oral T1D Adjunctive Therapy to Insulin

VTv Therapeutics: Q1 Earnings Snapshot

vTv Therapeutics Announces 2025 First Quarter Financial Results and Provides Corporate Update

vTv Therapeutics Announces Reinitiation of Screening in CATT1 Phase 3 Trial Evaluating Potential First-in-Class Liver-Selective Glucokinase Activator Cadisegliatin for Type 1 Diabetes

The Zacks Analyst Blog Highlights Sarepta Therapeutics, Incyte, Gilead Sciences and VTv Therapeutics

VTv Therapeutics: Q4 Earnings Snapshot

vTv Therapeutics Announces 2024 Fourth Quarter and Full Year Financial Results and Provides Corporate Update

FDA removes hold on vTv’s cadisegliatin clinical programme for diabetes

vTv Therapeutics Soars 43% as FDA Lifts Clinical Hold on Diabetes Drug Trial

FDA Lifts Clinical Hold-vTv Stock Jumps Nearly 28% on Diabetes Drug Progress

vTv Therapeutics Announces FDA has Lifted Clinical Hold on Cadisegliatin Program for Diabetes

We're Keeping An Eye On vTv Therapeutics' (NASDAQ:VTVT) Cash Burn Rate

CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF BRAIN METASTASIS FROM BREAST CANCER

vTv Therapeutics to Participate in 7th Annual Evercore HealthCONx Conference

vTv Therapeutics (NASDAQ:VTVT) adds US$9.5m to market cap in the past 7 days, though investors from five years ago are still down 71%

VTv Therapeutics: Q3 Earnings Snapshot

vTv Therapeutics Announces 2024 Third Quarter Financial Results and Provides Corporate Update

vTv Therapeutics Faces License Agreement Termination

VTv Therapeutics: Q2 Earnings Snapshot

vTv Therapeutics Announces 2024 Second Quarter Financial Results and Provides Corporate Update

Performance Overview